Scientists See Downsides to Top COVID-19 Vaccines from Russia, China

0
Representational photo. — Reuters

Allison Martell, Julie Steenhuysen | Reuters

TORONTO/CHICAGO  — High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.

CanSino Biologics’ (6185.HK) vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.

A vaccine developed by Moscow’s Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.

LEAVE A REPLY

Please enter your comment!
Please enter your name here